Please assess the completion status of the following clinical trial:

Trial Title: MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Children \> 1.0 months of age with a diagnosis of ADA-deficient SCID based on:~   * Confirmed absence (\<3% of normal levels) of ADA enzymatic activity in peripheral blood or (for neonates) umbilical cord erythrocytes and/or leukocytes, or in cultured fetal cells derived from either chorionic villus biopsy or amniocentesis, prior to institution of enzyme replacement therapy.~   AND~  * Evidence of severe combined immunodeficiency based on either:~     * Family history of first order relative with ADA deficiency and clinical and laboratory evidence of severe immunologic deficiency,~   OR~  * Evidence of severe immunologic deficiency in subject based on lymphopenia (absolute lymphocyte count \<200) or severely decreased T lymphocyte blastogenic responses to phytohemagglutinin (deltaCPM\<5,000), prior to institution of immune restorative therapy.~   OR~  * Fulfillment of criterion:~     * A in addition to evidence of genetic mutations affecting the ADA gene as determined by a CLIA certified laboratory and clinical evidence of combined immunodeficiency based on lymphopenia (absolute lymphocyte counts \<2SD of age-matched control values) and hypogammaglobulinemia (\<2SD of age-matched control values) or lack of specific antibody response to vaccination. In addition, for patients to be eligible under this criterion, they must present with a clinical history indicating life-threatening illness characterized by increased frequency and/or severity of infections resulting in hospitalization and/or the administration of intravenous antibiotics, for bacterial or opportunistic infection.~2. Ineligible for allogeneic (matched sibling) bone marrow transplantation (BMT):~   * Absence of a medically eligible HLA-identical sibling with normal immune function who may serve as an allogeneic bone marrow donor.~3. Written informed consent according to guidelines of the Institutional Review Board (IRB) at the University of California Los Angeles (UCLA).~This study is also open to delayed/late onset ADA-deficient patients who fulfill the criteria 1, 2.A, and 3 and who are not receiving PEG-ADA treatment after being invited to discuss all alternative treatment options with a physician not connected with the protocol.~Exclusion Criteria:~1. Age less than 1 month~2. Hematologic~   a. Anemia (hemoglobin \<10.5 mg/dl at \<2 years of age, or \< 11.5 at \>2 years of age,with normal serum iron studies). b. Neutropenia i. absolute granulocyte count \<500/mm3 or ii. absolute granulocyte count 500-999/mm3 (1 month - 1 year of age) or 500-1499/mm3 (\> 1 year of age)\] and bone marrow aspirate and biopsy showing myelodysplasia or other gross abnormality. c. Thrombocytopenia (platelet count 150,000/mm3, at any age). d. PT or PTT \>2X normal. e. Cytogenetic abnormalities on peripheral blood, or on cells collected by amniocentesis, if diagnosed in utero.~3. Infectious~   a. Evidence of active opportunistic infection or infection with HIV-1, hepatitis B, CMV or parvovirus B 19 by DNA PCR at time of assessment.~4. Pulmonary~   1. Resting O2 saturation by pulse oximetry \<95%.~  2. Chest x-ray indicating active or progressive pulmonary disease.~5. Cardiac~   1. Abnormal electrocardiogram (EKG) indicating cardiac pathology.~  2. Uncorrected congenital cardiac malformation.~  3. Active cardiac disease, including clinical evidence of congestive heart failure,cyanosis, hypotension.~6. Neurologic~   1. Significant neurologic abnormality by examination.~  2. Uncontrolled seizure disorder.~7. Renal~   1. Renal insufficiency: serum creatinine \> or = 1.2 mg/dl, or \> or = 3+ proteinuria.~  2. Abnormal serum sodium, potassium, calcium, magnesium, phosphate at grade III or IV by Division of AIDS Toxicity Scale.~8. Hepatic/GI:~   1. Serum transaminases \> 5X normal.~  2. Serum bilirubin \> 3.0 mg/dl.~  3. Serum glucose \> 250mg/dl.~  4. Intractable severe diarrhea.~9. Oncologic (see below\*)~   1. Evidence of active malignant disease other than dermatofibrosarcoma protuberans (DFSP)~  2. Evidence of DFSP expected to require anti-neoplastic therapy within the 5 years following the infusion of genetically corrected cells~  3. Evidence of DFSP expected to be life limiting within the 5 years following the infusion of genetically corrected cells~10. Known sensitivity to Busulfan~11. General~    1. Expected survival \<6 months.~   2. Pregnant.~   3. Major congenital anomaly.~   4. Medically eligible HLA-matched sibling.~   5. Other conditions which in the opinion of the P.I. or co-investigators, contra-indicate infusion of transduced cells or indicate patient's inability to follow protocol.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Retroviral-mediated ADA gene transfer (Type: EXPERIMENTAL): Transfer of the human ADA gene to isolated CD34+ cells from the bone marrow.

Based on this trial design, predict the completion outcome and termination type (if applicable).